Featured Reports, News & Insights
Due to Aducanumab’s New PDUFA Date, ICER Extends Timeline for Alzheimer’s Disease Assessment
ICER extended the timeline for assessing the comparative clinical effectiveness and value of aducanumab (Biogen) for the treatment of Alzheimer’s disease.
02/10/2021ICER Identifies Most Significant 2019 US Drug-Price Hikes — Even After Rebates — That Were Not Supported by New Clinical Evidence
Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.
01/12/2021ICER Publishes Evidence Report on Roxadustat for Treating Anemia in Chronic Kidney Disease
Other than a proven ability to reduce the need for IV iron supplements, the evidence is insufficient to determine if roxadustat is safer or more effective than ESAs; possibility exists for greater mortality than ESAs.
01/28/2021